biotech, you know as well as I do that planning an AD trial
biotech, you know as well as I do that planning an AD trial takes many months of work. No one is going to plan to use LymPro in their trial until that product is actually available for use in the trial, which was only a short time ago. Based on the feedback the company received from researchers and Key Opinion Leaders prior to the commercial launch, I remain confident that LymPro is currently included in the planning stages of many upcoming drug trials. When those are finalized and the contracts are signed, the company will make the appropriate announcements, and not before.
Some have so little faith and patience that they quickly assume that with only one small trial announced so far, that LymPro is a dud and no one is interested. Since many of you boast about critical thinking and being objective, where's the critical thinking when it comes to the AD trial planning time. If one considers that, then the calendar math would indicate there could be a multitude of trial announcements involving LymPro to be revealed in the coming months.
Have a little patience. If we get to June and we still don't have any additional trials using LymPro, I will start to be concerned that perhaps things aren't working out as we expected.
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Greenlight Networks Expands Fiber Internet Services Greenlight Networks, a prominent fiber-to-the-home internet provider, is set to expand its fiber services into a new area with a significant investment of $100 million. This expansion aims to enhance high-speed internet access for residents and small businesses, ushering in new opportunities for economic growth and...
Continue Reading
Understanding Meta Platforms in the Market In the rapidly evolving business environment, it’s crucial for investors to closely examine firms prior to making investment choices. This article will provide a detailed analysis of Meta Platforms (NASDAQ: META) within the context of its main rivals in the Interactive Media & Services sector. By reviewing essential financial...
Continue Reading
Exploring Preliminary Data on Early Redemptions In light of recent financial insights, Jyske Realkredit has released preliminary data regarding early redemptions, specifically focusing on prepayments related to bonds. This intriguing announcement is intended for stakeholders and interested parties looking to understand the dynamics of the bond market. Understanding Early...
Continue Reading
Eltek Ltd. Announces Strong Performance for Q3 2024 Eltek Ltd. (NASDAQ: ELTK), a world-leading manufacturer of advanced printed circuit board solutions, has recently reported remarkable financial results for its third quarter, demonstrating a meaningful surge in revenues and profits. The company’s commitment to innovative practices in the PCB sector is reflected in its...
Continue Reading
Excitement Grows for Palantir Technologies' AI Conference As Palantir Technologies prepares for its upcoming conference focused on artificial intelligence, industry experts are eagerly anticipating the insights that could come from this significant event. A key topic of discussion is the recent extension of Palantir's partnership with a major energy player. Strategic...
Continue Reading